Evidence map›Paper›PMID 31649864›Full record

ReviewPerspectives in clinical research

Biovigilance: A Global Perspective.

Sukhjinder Singh, Shammy Chandel, Phulen Sarma, Dibbanti Harikrishna Reddy, Abhishek Mishra, Subodh Kumar, Prasad Thota, Kotni Murali, Ajay Prakash, Bikash Medhi

Open access · diamondAbstract readReview
In one paragraph

Review in Perspectives in clinical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sukhjinder SinghDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Shammy ChandelDepartment of Neurosurgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Phulen SarmaDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Dibbanti Harikrishna ReddyDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Abhishek MishraDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Subodh KumarDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Prasad ThotaDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Kotni MuraliDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Ajay PrakashDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Bikash MedhiDepartment of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A biological is a substance which either comprises, contains, or is derived from human cells or human tissues. The use of biological products is associated with the risk of infection transmission, allergic reactions, and other adverse events (AEs). The science and activities relating to the detection, assessment, understanding, and prevention of AEs or any other problems related to biological products (blood, cells, tissues, organs, and vaccine in international perspective) are termed as biovigilance. With more and more biologicals being marketed and the rapid revolutionary changes in transplant-related services, the importance of biovigilance is increasing day by day. Although specific types of vigilance systems (pharmacovigilance and materiovigilance) exist, activities related to "biovigilance" are still in an infancy stage. Many developed countries such as the USA, Europe, and Australia have implemented nationwide biovigilance programs. In India, the National Institute of Biologicals, in collaboration with the Indian Pharmacopoeia Commission, has launched the Biovigilance Programme of India. In this article, the biovigilance systems of different countries across the globe have been reviewed along with highlights of the current biovigilance needs.

Indexed as

Adverse eventsbiological productsbiovigilance

Identifiers

PMID31649864
PMCPMC6801993
OpenAlexW2972197448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.